As the first product capable of simultaneously profiling up to 5 histone post‑translational modifications together with DNA methylation across multiple samples, EpiFinder™ cNUC offers researchers an entirely new way to obtain scalable, high‑resolution epigenomic information from low‑volume liquid biopsy samples.
With the ability to run up to 24 samples in a single workflow, EpiFinder™ cNUC reduces hands‑on time and technical variability while generating robust and quantitative data without the need for spike‑in controls. Its innovative chemistry enables the simultaneous analysis of up to six epigenetic marks from just 200 µL of sample, providing powerful insights in studies where sample availability is limited.
The product profiles epigenetic marks directly from circulating nucleosomes, without requiring nucleosome extraction, preserving biological integrity, simplifying the workflow, and saving the cost of DNA purification. EpiFinder™ cNUC is complemented by an intuitive open‑source data analysis pipeline that requires no advanced bioinformatics expertise, enabling researchers to move seamlessly from data generation to biological interpretation.
Its flexible design allows users to tailor sample throughput and selected epigenetic markers to match project objectives, from early exploratory studies to large‑scale biomarker development efforts. Combined high-throughput and multiplexing also deliver significant cost efficiency, reducing the cost per sample and expanding access to comprehensive epigenomic studies.
“With EpiFinder™ cNUC, we aim to make epigenomics more accessible, scalable, and actionable for researchers working to understand complex diseases,” said Mohamad Takwa, CEO of Epigenica. “By enabling direct and multiplexed analysis of circulating nucleosomes, this product brings a new level of clarity to liquid biopsy research and supports the scientific community in accelerating discoveries that can ultimately benefit patients.”
Engineered to support biomarker discovery and translational research across oncology, aging, inflammation, and other therapeutic areas, EpiFinder™ cNUC delivers the depth and resolution needed for drug development, early disease detection, patient stratification, disease‑progression monitoring, and treatment‑response evaluation. By enabling a multidimensional view of circulating nucleosome biology at scale, the product sets up a new standard for epigenomics in liquid biopsy.
EpiFinder™ cNUC is available as a kit or as a fully supported service tailored to your needs.
For product details or purchasing information, visit www.epigenica.se or contact sales@epigenica.se